Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 430-432

  De Dios, C ^a   Fudio, S ^a   Lorenzo, A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

cognitive decline; induced parkinsonism; quetiapine; valproic acid

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; QUETIAPINE; VALPROIC ACID;

AGED; ARTICLE; BIPOLAR DISORDER; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; FOLLOW UP; HUMAN; MANIA; NEUROIMAGING; PARKINSONISM; TREATMENT OUTCOME;

AGED; ANTIMANIC AGENTS; BIPOLAR DISORDER; COGNITION DISORDERS; CYTOCHROME P-450 CYP3A; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PARKINSON DISEASE, SECONDARY; TREATMENT OUTCOME; VALPROIC ACID;

EID: 79955749528     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01197.x     Document Type: Article

References (12)

1. Armon C, Shin C, Miller P, (1996) Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology, 47, 626-635. (Pubitemid 26307288)
2. Masmoudi K, Gras-Champel V, Bonnet I, (2000) Dementia and extrapyramidal problems caused by long-term valproic acid. Therapie, 55, 629-634. French
3. Gaubert ML, Cougnaud A, Ghali A, Bruhat C, Diquet B, Berrut G, (2006) Loss of autonomy related to valproic acid intake. Journal of the American Geriatrics Society, 54, 1971. (Pubitemid 44915867)
4. Masmoudi K, Gras-Champbel V, Masson H, (2006) Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsyquiatry, 39, 9-12. (Pubitemid 43235443)
5. Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, Lang A, (2007) Movement disorders in patients taking anticonvulsants. Journal of Neurology, Neurosurgery and Psychiatry, 78, 147-151. (Pubitemid 46220211)
6. Ricard C, Martin K, Tournier M, Bégaud B, Verdoux H, (2005) A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder. Encephale, 31, 98-101. (Pubitemid 40459925)
7. Del Bello MP, Schwiers ML, (2002) A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1216-1223. (Pubitemid 38338041)
8. Seeman P, Tallerico T, (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Molecular Psychiatry, 3, 123-134. (Pubitemid 28149553)
9. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G, (2006) Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. International Clinical Psychopharmacology, 21, 81-85. (Pubitemid 43740314)
10. Winter HR, Devane CL, Figueroa C, Ennis DJ, Hamer-Maansson JE, Davis PC, Smith MA, (2007) Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Human Psychopharmacology, 22, 469-476. (Pubitemid 47611302)
11. Habermeyer B, Rabovsky K, Jentzsch C, Pinhard K, Müller-Spahn F, (2007) Cervical dystonia due to interaction of valproic acid and quetiapine. Journal of Clinical Psychopharmacology, 27, 396-397. (Pubitemid 47075514)
12. Karch FE, Lasagna L, (1997) Toward the operational identification of adverse drug reactions. Clinical Pharmacology and Therapeutics, 21, 247-254.